Literature DB >> 28115245

Autologous method for ex vivo expansion of human limbal epithelial progenitor cells based on plasma rich in growth factors technology.

A C Riestra1, N Vazquez2, M Chacon2, S Berisa2, R M Sanchez-Avila2, G Orive3, E Anitua4, A Meana5, J Merayo-Lloves2.   

Abstract

PURPOSE: Develop an autologous culture method for ex vivo expansion of human limbal epithelial progenitor cells (LEPCs) using Plasma Rich in Growth Factors (PRGF) as a growth supplement and as a scaffold for the culture of LEPCs.
METHODS: LEPCs were cultivated in different media supplemented with 10% fetal bovine serum (FBS) or 10% PRGF. The outgrowths, total number of cells, colony forming efficiency (CFE), morphology and immunocytochemistry against p63- α and cytokeratins 3 and 12 (CK3-CK12) were analyzed. PRGF was also used to elaborate a fibrin membrane. The effects of the scaffold on the preservation of stemness and the phenotypic characterization of LEPCs were investigated through analysis of CK3-CK12, ABCG-2 and p63.
RESULTS: LEPCs cultivated with PRGF showed a significantly higher growth area than FBS cultures. Moreover, the number of cells were also higher in PRGF than FBS, while displaying a better morphology overall. CFE was found to be also higher in PRGF groups compared to FBS, and the p63-α expression also differed between groups. LEPCs cultivated on PRGF membranes appeared as a confluent monolayer of cells and still retained p63 and ABCG-2 expression, being negative for CK3-CK12.
CONCLUSIONS: PRGF can be used in corneal tissue engineering, supplementing the culture media, even in a basal media without any other additives, as well as providing a scaffold for the culture.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell culture techniques; Cell proliferation; Cell transplantation; Corneal epithelium; Culture media; Limbal deficiency; Limbus corneae; PRGF; Plasma rich in growth factors

Mesh:

Year:  2017        PMID: 28115245     DOI: 10.1016/j.jtos.2017.01.003

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  7 in total

Review 1.  Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization.

Authors:  Eduardo Anitua; Mar Zalduendo; Maria Troya; Mohammad H Alkhraisat; Leticia Alejandra Blanco-Antona
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

Review 2.  Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy.

Authors:  Antonio J Villatoro; Viviana Fernández; Silvia Claros; Cristina Alcoholado; Manuel Cifuentes; Jesús Merayo-Lloves; José A Andrades; José Becerra
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

3.  Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders.

Authors:  Ronald M Sanchez-Avila; Jesús Merayo-Lloves; Ana C Riestra; Silvia Berisa; Carlos Lisa; José Alfonso Sánchez; Francisco Muruzabal; Gorka Orive; Eduardo Anitua
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  Plasma Rich in Growth Factors in Macular Hole Surgery.

Authors:  Ronald M Sánchez-Ávila; Carlos A Robayo-Esper; Eva Villota-Deleu; Álvaro Fernández-Vega Sanz; Álvaro Fernández-Vega González; Borja de la Sen-Corcuera; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Clin Pract       Date:  2022-01-10

5.  Autologous Platelet Rich Plasma (PRGF) Preserves Genomic Stability of Gingival Fibroblasts and Alveolar Osteoblasts after Long-Term Cell Culture.

Authors:  Eduardo Anitua; María de la Fuente; María Troya; Mar Zalduendo; Mohammad Hamdan Alkhraisat
Journal:  Dent J (Basel)       Date:  2022-09-14

6.  Fibrin-Plasma Rich in Growth Factors Membrane for the Treatment of a Rabbit Alkali-Burn Lesion.

Authors:  Ronald M Sánchez-Ávila; Natalia Vázquez; Manuel Chacón; Mairobi Persinal-Medina; Agustín Brea-Pastor; Silvia Berisa-Prado; Luis Fernández-Vega-Cueto; Eduardo Anitua; Álvaro Meana; Jesús Merayo-Lloves
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

7.  Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors.

Authors:  Ronald M Sánchez-Ávila; Álvaro Fernández-Vega González; Álvaro Fernández-Vega Sanz; Jesús Merayo-Lloves
Journal:  Int Med Case Rep J       Date:  2019-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.